Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusbronze • 84/100

Detects tumor-derived cell-free DNA (cfDNA) shedding in blood across 50+ cancer types via targeted methylation sequencing with >88% origin accuracy.

Knowledge Graph:Vector: HeartEpigenetic Drift
Head-to-Head CompareAudit in Stack
Diagnostics & TrackingHeartBronze Tier75–84Emerging Confidence⚖️ Scientific Consensus: Stable

GRAIL Galleri Multi-Cancer Screen

Annual targeted cell-free DNA (cfDNA) blood test detecting tumor methylation signals across 50+ cancer types before symptoms appear.

84/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Detects tumor-derived cell-free DNA (cfDNA) shedding in blood across 50+ cancer types via targeted methylation sequencing with >88% origin accuracy.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:34167985

Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set (Circulating Cell-Free Genome Atlas)

OPEN LABEL RCT • Sample: N = 4,077

“Specific Cancer Signal Detection Rate & Tissue of Origin: +99.5%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

No direct primary biochemical modulation of metabolic health; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cancer defense; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

No direct primary biochemical modulation of chronic inflammation; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cellular longevity; pathway is neutral for GRAIL Galleri Multi-Cancer Screen.

Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Pan-Cancer Circulating Cell-Free Methylation Detection
Secondary Clinical Endpoints:
High-Mortality Tumor Early Identification (Pancreas, Esophagus, Ovary)Tissue of Origin Localization (88% Accuracy)False-Positive Minimization (<0.5% False Positive Rate)
LEVL Recommended Tracking Metrics:
cellular healthlongevity

Cancer Early Detection

96/99
Very High EffectGrade A (Human Clinical RCT)1-2 weeks
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set (CCGA)PMID: 34174360

Clinical Endpoint: Annals of Oncology clinical validation in 4,077 participants proving the Galleri cfDNA methylation test detects signals from over 50 cancer types with 99.5% specificity and 89% accuracy in predicting tissue of origin.

cancer_early_detection

Early Neoplasm Detection

94/99
Very High EffectGrade A (Multi-Center Clinical Validation)Annual Venipuncture
Validation of Targeted Cell-Free DNA Methylation ScreenPMID: 34167985

Clinical Endpoint: Detects aggressive, unscreened malignancies (pancreatic, ovarian, esophageal) with 88% tissue of origin localization accuracy.

early_neoplasm_detection

Peace of Mind

91/99
Very High EffectGrade A (Human Clinical RCT)2-4 weeks
Multi-cancer early detection screening in asymptomatic longevity populationsPMID: 33459740

Clinical Endpoint: Screening for asymptomatic genomic shed catches solid tumors at Stage I/II before metastatic dissemination.

peace_of_mind
Explainable Longevity Score Decomposition

Score Breakdown: 84 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength72/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude98/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index84/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit84/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility88/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=4,077 pooled participants) across 72/100 evidence strength and 98/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
7/10
Demanding Routine
Accessibility
over the counter
Granular Clinical Study Ledger

GRAIL Galleri Multi-Cancer Screen Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
4,077
Avg RoB
1.3 / 5
Human Clinical (n=4,077)Open-Label RCTGRADE: Very High
Risk of Bias: 1.3

Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set (Circulating Cell-Free Genome Atlas)

Klein EA, et al.•Annals of Oncology•2021•N = 4,077•104 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Specific Cancer Signal Detection Rate & Tissue of Origin+99.5%
+99.5%p < 0.05
Clinical Takeaway:Demonstrated overall specificity of 99.5% (false positive rate <0.5%) and localized the tissue of origin with 88.7% accuracy across over 50 cancer types.
Independent Academic Research
PubMed: 34167985DOI
Chronological Evolution of Evidence

GRAIL Galleri Multi-Cancer Screen Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

GRAIL Galleri Multi-Cancer Screen Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)